Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 28  |  Issue : 1  |  Page : 254-258

Biomarker predictors of survival in patients with ventilator-associated pneumonia


1 Department of Anaesthesia and Critical Care, Menoufia University, Menoufia Governorate, Egypt
2 Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia Governorate, Egypt

Correspondence Address:
Asmaa E Salama
Department of Anaesthesia and Critical Care, Faculty of Medicine, Menoufia University, Kamshish, Tala, Menoufia Governorate
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-2098.156004

Rights and Permissions

Objective The aim of this study was to determine the role of procalcitonin (PCT) and C-reactive protein (CRP) as predictors of survival in ventilator-associated pneumonia (VAP) and determine the most common micro-organisms involved in VAP in the Menofiya University Hospital ICU. Background The prediction of survival in VAP remains a major challenge. We evaluated the performance of clinical score [Sequential Organ Failure Assessment (SOFA)], PCT, and CRP threshold values and kinetics as predictors of VAP survival. Materials and methods A total of 50 patients with VAP were studied at the Menofiya University Hospital ICU. Acute Physiology And Chronic Health Evaluation II (APACHE II) score was assessed during first 24 h of admission; clinical pulmonary infection score was followed up in mechanically ventilated patients for diagnosis of VAP. SOFA score, serum CRP, and serum PCT were assessed on day 1, day 4, and day 7 of VAP diagnosis and were correlated with the 28-day survival/mortality. Patients who survived were considered survivors (group A), and patients who died before 28 days were considered nonsurvivors (group B). Results The 28-day mortality rate was 40%. The APACHE II score was significantly lower in survivors than nonsurvivors (P < 0.001). Serum PCT was significantly lower on days 4 and 7 in the survivor group (504.87 ± 267.28, 164.30 ± 98.56 pg/l, respectively) in comparison with the nonsurvivor group (930.30 ± 177.54, 897.35 ± 200.99 pg/l) with a P-value of less than 0.001. The SOFA score was significantly lower on days 1, 4, and 7 in the survivor group (5.73 ± 1.80, 4.57 ± 1.22, 3.63 ± 1.16) compared with the nonsurvivor group (7.95 ± 1.39, 8.60 ± 1.53, 9.85 ± 1.90, respectively), with a P-value of less than 0.001. Serum CRP was comparable on days 1, 4, and 7 days in the survivor (108.0 ± 55.93, 103.60 ± 43.69, 85.6 ± 58.68 mg/dl) and the nonsurvivor group (108.0 ± 46.39, 100.80 ± 51.41, 100.80 ± 58.06 mg/dl), respectively. Age was significantly higher in the nonsurvivors than the survivors (61.30 ± 15.60, 46.93 ± 18.25, respectively) (P = 0.002). Conclusion The SOFA score can predict survival in VAP. The serum level of PCT can be used for diagnosis of VAP. PCT kinetics can be used to assess prognosis in VAP patients. CRP is useful as a diagnostic but not as a prognostic biomarker in VAP.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed819    
    Printed8    
    Emailed0    
    PDF Downloaded159    
    Comments [Add]    

Recommend this journal